Drug Profile
Iruplinalkib - Qilu Pharmaceuticals
Alternative Names: FL-006; WX-0593Latest Information Update: 02 Feb 2024
Price :
$50
*
At a glance
- Originator Qilu Pharmaceutical
- Class Amines; Antineoplastics; Benzene derivatives; Chlorinated hydrocarbons; Phosphorus compounds; Pyrimidines; Small molecules; Spiro compounds
- Mechanism of Action Anaplastic lymphoma kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Non-small cell lung cancer
- Phase I/II Solid tumours
Most Recent Events
- 30 Jan 2024 Interim adverse events and efficacy data from a phase III INSPIRE trial in Non-small cell lung cancer released by Qilu Pharmaceutical
- 09 Sep 2023 Adverse events data from a phase III INSPIRE trial in Non-small cell lung cancer presented at the 24th World Conference on Lung Cancer (WCLC-2023)
- 17 Aug 2023 Preregistration for Non-small cell lung cancer (First-line therapy, Late-stage disease, Metastatic disease) in China (PO), prior to August 2023